CLINICAL_TRIALS
trial_result
· 2014-11-20
Clinical Trial Update: A Twelve Week, Open Label Extension Study in Patients With Schizophrenia [Phase 3]
Summary
A twelve-week open-label extension study (Phase 3) in schizophrenia was completed with results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Sumitomo Pharma America, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2014-11-20